4.7 Letter

Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy

Related references

Note: Only part of the references are listed.
Letter Urology & Nephrology

Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy

Sofiane Salhi et al.

KIDNEY INTERNATIONAL (2021)

Review Urology & Nephrology

Plasma cells as an innovative target in autoimmune disease with renal manifestations

Falk Hiepe et al.

NATURE REVIEWS NEPHROLOGY (2016)